Since glycosylation of MUC1 in cancer cells is distinct from mucin expressed in healthy tissue (Hanisch and Muller, 2000), tumour-associated mucin represents a valuable target for diagnostic and therapeutic approaches with monoclonal antibodies (mAbs). This evidence concerns the gene MUC1 and neoplasm.